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Mitochondria are the most eﬃcient producers of energy in the form of ATP. Energy demands of axons, placed at relatively
great distances from the neuronal cell body, are met by mitochondria, which when functionally compromised, produce reactive
oxygen species (ROS) in excess. Axons are made metabolically eﬃcient by myelination, which enables saltatory conduction.
The importance of mitochondria for maintaining the structural integrity of myelinated axons is illustrated by neuroaxonal
degeneration in primary mitochondrial disorders. When demyelinated, the compartmentalisation of ion channels along axons
is disrupted. The redistribution of electrogenic machinery is thought to increase the energy demand of demyelinated axons. We
review related studies that focus on mitochondria within unmyelinated, demyelinated and dysmyelinated axons in the central
nervous system. Based on neuropathological observations we propose the increase in mitochondrial presence within demyelinated
axons as an adaptive process to the increased energy need. An increased presence of mitochondria would also increase the capacity
to produce deleterious agents such as ROS when functionally compromised. Given the lack of direct evidence of a beneficial or
harmful eﬀect of mitochondrial changes, the precise role of increased mitochondrial presence within axons due to demyelination
needs to be further explored in experimental demyelination in-vivo and in-vitro.
1. Introduction
Axons are unique structures in the central nervous system
with much of their cytoplasm found at great distances from
the neuronal cell body. Myelination of axons is essential
for fast conduction of action potentials and their metabolic
eﬃciency [1]. Axonal degeneration in demyelinating diseases
such as multiple sclerosis (MS) indicates the importance
of trophic support that myelin lends to axons whilst also
providing protection from various extracellular insults.
Mitochondria, the ubiquitous energy-producing organelles,
are found within axons. They are vastly dynamic and locate
to areas in which they are most needed and, as we will discuss
in this review, appear highly adaptable to subtle energy
changes within the axon. We review mitochondrial changes
that follow demyelination and indicate the damaging conse-
quences of mitochondrial failure for axons.
2. Mitochondria
Mitochondria are charged with supplying the vast amount
of ATP required in eukaryotic cells. Other important roles in
calcium buﬀering and apoptosis cannot be underestimated
[2]. The respiratory chain which is responsible for the
process of oxidative phosphorylation, ultimately resulting in
the production of ATP from ADP, consists of complex I–
complex IV and an additional ATP synthase.
Mitochondria contain the only extranuclear DNA in
the cell (mtDNA). The mitochondrial genome holds 13
protein encoding genes which incorporate into complex I,
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complex III, complex IV, and ATP synthase. Complex II
is the only complex with all subunits encoded by nuclear
DNA, which, from an investigative point of view, is highly
advantageous [3, 4]. MtDNA mutation (point mutations
and deletions) led energy deficiency states frequently aﬀect
the central nervous system (CNS) in patients with primary
mitochondrial diseases.
3. A Question of Energy for Axons
The vast energy requirement of axons is highlighted by the
location of the sodium potassium ATPase (Na+/K+ ATPase)
which extends along myelinated segments of the axons
(internodes) [5]. The Na+/K+ ATPase facilitates the rapid
exchange of sodium for extracellular potassium, through the
process of active transport and is thus a major consumer
of energy in the CNS [6]. Sodium channels play an
important role in axons, and their clustering at the nodes of
Ranvier facilitate the fast propagation of action potentials or
“saltatory conduction” and allow influx of sodium into the
axon. Diﬀerent isoforms exist, but the accepted forms known
to exist in neurons are Nav1.1, Nav1.2, and Nav1.6. Those
expressed on axonal membranes are predominantly Nav1.2
and Nav1.6 [7]. The importance of the persistent sodium
influx allowed by Nav1.6 is highlighted by the redistribution
of the channel along nonmyelinated axons tomaintain action
potentials [8]. During development in the premyelination
state, Nav1.2 channels support action potentials [9] which
are soon replaced following myelination with Nav1.6 chan-
nels, identified to allow a persistent current of sodium.
Myelin also induces the clustering of sodium channels at
nodes of Ranvier [10]. In the CNS, mitochondria were
presumed to reside in the nonmyelinated segments, nodes of
Ranvier, based on findings in the peripheral nervous system
(PNS); however, recent evidence suggests that mitochondria
preferentially locate in the internodes [11], at least in small
diameter axons, which would fit with the energy demand
hypothesis. Evidence for the need of precise location of
mitochondria within axons is observed in growth cones. An
elegant study by Morris and Hollenbeck in 1993 showed that
the presence of mitochondria in neurons is coordinated with
axonal outgrowth. They showed that by blocking the growth
of a number of axons and then visualising the mitochondrial
content, the preferential location of the mitochondria was in
the outgrowing axons, particularly in the terminal ends [12].
Whilst ATP can readily diﬀuse into the cytosol, it appears that
the precise location of mitochondria is important.
Axons, both myelinated and unmyelinated, are an
excellent forum to understand the relationship between
mitochondria and the diﬀering energy demands of the CNS,
given the diﬀerence in ion channel expression in these axons
[13]. The lamina cribrosa is a region of the optic nerve that
is unmyelinated with myelination of fibres occurring at the
posterior border. Complex IV activity was assessed in fibres
of the lamina cribrosa [3]. Complex IV consumes 90% of
cellular oxygen [2] and is involved in proton pumping across
the inner mitochondrial membrane. Perhaps, importantly,
numerous inhibitors of complex IV exist including nitric
oxide, a competitive inhibitor [14], whilst its more toxic
derivative, peroxynitrite, can irreversibly inhibit both com-
plex I and complex IV [15]. Complex IV activity was found
to be vastly increased in the unmyelinated segment compared
to the myelinated segment which corresponded with an
increase in complex IV subunit II protein level [16, 17]. The
distribution of complex IV activity correlated with certain
isoforms of sodium channels. Both Nav1.1 and Nav1.6 were
found to increase in intensity with lack of myelin whilst there
was little predilection for Nav1.2 in either region [18]. These
findings in control subjects suggest a physiological role for
the increased presence of mitochondria in the unmyelinated
segments compared with myelinated segments of optic nerve
axons.
4. Loss of Compartmentalisation
of Electrogenic Machinery and
a Question of Energy for
Demyelinated and Dysmyelinated Axons
Several groups have predicted metabolic changes within
axons based on changes in ion channel distribution following
demyelination and dysmyelination (Figure 1) [19–21]. There
has been a number of studies with animal models in which
genes for myelin proteins have been knocked out or toxic
insults to myelin have been introduced.
In a mouse model of hypomyelination caused by gene
knockout encoding the myelin basic protein gene, complex
IV activity was found to be increased associated with an
increase in mitochondrial density suggestive of adaptive
changes to this change in myelin [20]. Furthermore, in a
proteolipid protein (PLP) overexpressing mouse model, dys-
myelination at 1 month followed by complete demyelination
at 4 months was associated with an increase in mitochondrial
density and complex IV activity compared to wild type [19].
Axonal degeneration was not evident at this time point. In a
hemizygous PLP overexpressing mouse model predisposing
to only partial demyelination, whilst mitochondrial density
increased, complex IV activity remained similar to wild type.
Electron microscopy revealed the presence of degenerating
axons suggesting a lack of compensation from complex
IV predisposed to the phenotype. These animal models
show the relationship between disruptions to myelin and
changing energy demands compensated for by alterations in
mitochondria.
In one particular model in which antiserum to galac-
tocerebroside was used to selectively demyelinate cat optic
nerve, a significant increase in mitochondrial number was
observed which reached a peak at seven days after injection
[21]. The authors suggest that this is an adaptive feature
of the demyelinated axons particularly as this coincided
with a change from conduction block to slowed conduction
[22]. In a demyelination model induced by Theiler’s murine
encephalomyelitis virus (TMEV), neurological dysfunction
results from progressive nervous system demyelination.
Mitochondrial numbers were found to be significantly
increased in demyelinated axons compared to controls
[23]. Interestingly, mitochondrial numbers correlated well
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Figure 1: Mitochondrial changes within axons in response to demyelination and further cytoskeletal injury. Sodium channels (Nav1.6)
are located at nodes of Ranvier in the CNS whilst the Na+/K+ ATPase extends the myelinated segments (internodes). To facilitate the
extended energy demand of the axon, mitochondria have been shown to distribute throughout the axonal cytoplasm in small axons in
the CNS (green). The redistribution of sodium channels facilitates the continuation of action potentials along the demyelinated axons
(blue). Mitochondrial dysfunction can leave the axon vulnerable as observed in acute and chronic stages of MS (red). It is hypothesised
that the failure of the Na+/K+ ATPase, possibly due to mitochondrial dysfunction, can lead to increased sodium concentrations in the
axoplasm. Reversal of the Na+/Ca2+ exchanger can ensue, resulting in toxic calcium levels and downstream processes with consequent axonal
degeneration. Mitochondrial dysfunction (red) possibly by inflammatory products such as nitric oxide (NO) and peroxynitrite (ONOO−)
can lead to membrane depolarisation and retrograde transport toward the neuronal soma (arrow to the left). A population of axons have
been shown to exist without the Na+/K+ ATPase which would also have a similar eﬀect to an energy defect.
with the percentage of total spinal cord demyelination
and strong correlations were found between the number
of degenerating axons and intra-axonal mitochondria in
demyelinated axons, raising the possibility that increases of
intra-axonal mitochondria may be detrimental to axons.
Mitochondrial density was still increased after 6 months.
Our view, partly supported by observations in unmyelinated
axons, is that an increase in mitochondria per se, as long
as the function is not compromised, is not damaging to
the axons. However, mitochondrial defects in situations of
elevated energy needs, as seen in some demyelinated axons,
may be even more detrimental due to the toxic eﬀects of
dysfunctional mitochondria.
Mitochondrial defects in experimental demyelinating
models implicate the organelle in the pathogenesis of axonal
degeneration. Post-translational modification of mitochon-
drial respiratory chain subunits as well as transcriptionally
regulated changes in mitochondrial function have been
observed in animal models of MS [24–27]. Moreover, the
addition of reactive oxygen species scavengers resulting
in decreased optic nerve degeneration suggests a role for
mitochondrial injury via oxidative stress and identifies
mitochondrially targeted agents as potential therapy in MS
[28].
5. The Importance of Mitochondrial
Transport, Fusion, Fission,
and Biogenesis for Demyelinated Axons
The observation of an increased mitochondrial presence
within demyelinated axons raises a number of important
questions including how the mitochondrial changes occur.
The possible explanations include an increase in anterograde
transport, decrease in retrograde transport, increase in
fusion, decrease in fission, and mitochondrial biogenesis
within axons.
Neurons have developed a highly sophisticated transport
system to meet the needs of the axon with machinery
for both transport of proteins away from the cell body,
into the far reaches of the axon, anterograde transport,
and a system to transport aberrant proteins back to the
cell body for degradation, retrograde transport. Two pools
of mitochondria exist in axons, those that are stationary,
which comprise 70% of axonal mitochondria, and those
that are mobile. Mobile mitochondria have been found
to move on both microtubules and actin-microfilaments
within the axon. A 1995 study used toxic agents which
were applied to axons that disrupted either microtubules
or actin-microfilament [29]. The authors concluded that
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mitochondrial velocity within axons is determined by co-
ordination of microtubule and actin-microfilament based
movements.
There are two motor transport systems responsible for
anterograde and retrograde movements of mitochondria,
kinesins and dyneins, respectively. Kinesin motors are
responsible for anterograde transport whilst dynein motors
are responsible for retrograde transport along microtubules.
Kinesins of the kinesin-1 family associate with mitochondria
as well as vesicles containing, among other proteins, amyloid
precursor protein (APP). Sites of APP accumulation in
postmortem tissues are readily used to detect disruption of
fast axonal movement [30, 31]. Inhibition of kinesin-1 in
Drosophila melanogaster has been shown to inhibit mito-
chondrial transport [32]. The importance of anterograde
mitochondrial transport is highlighted by mutations of one
member of the kinesin family, Kif1β, shown to transport
mitochondria. These mutations can lead to the axonal form
of Charcot-Marie-Tooth disease (CMT2a). Heterozygous
knockout mice showed symptoms similar to CMT2a with
progressive muscle weakness. The ATPase activity of the
motor was found to be reduced, thus, suggestive of a
functional loss of motor activity [33]. Retrograde movement
of microtubules appears to require dynein motors [34],
although it is known that several kinesin motor families have
retrograde movement, however, the velocity at which these
move indicates they are unlikely to be involved in axonal
mitochondrial transport. Myosin motors are implicated on
actin-microfilaments due to the bidirectional movement of
mitochondria. Myosin V is a likely candidate as it has been
shown to move organelles at similar rates as observed with
mitochondria in axons [29].
It is clear from recent studies that retrograde movement
of mitochondria occurs in situations of mitochondrial dys-
function. For instance in familial amyotrophic lateral sclero-
sis where mutations in the antioxidant enzyme Cu/Zn super-
oxide dismutase-1 (SOD1) which accounts for 20% of all
familial cases, it has been shown that this mutation inhibits
anterograde transport but not retrograde transport [35].
Furthermore, when the complex III inhibitor, antimycin, was
used in a cell culture model of neurons derived from dorsal
root ganglion, the number of mitochondria associated with
retrograde transport significantly increased [36].
There was understood to be a mitochondrial docking
protein for the stationary pool in axons although the actual
identity of this protein remained unknown for some years.
In a recent study, syntaphilin, a neuron-specific protein was
identified as this docking protein [37]. The authors show
that mitochondria and syntaphilin colocalise within axons,
syntaphilin immobilises the organelle, and in syntaphilin
knockout mice mitochondrial motility increased but their
number significantly reduced in axons.
Mitochondria are far more dynamic organelles than
depicted in textbook images, existing in networks rather
than in isolation. Large networks of mitochondria can
form through the process of fusion and can be broken
up through the action of fission. Mitochondrial fusion
machinery consists of the mitofusins MTF1 and MTF2 as
well as the GTPase OPA1, responsible for both outer and
inner membrane fusion, respectively [38]. DRP1 is the key
regulator of mitochondrial fission [39]. The importance of
these processes can be observed again in CMT2a which
is associated with a number of mutations in MFN2 [40].
Similarly, mice that lack MFN1, MFN2, or OPA1, all
responsible for mitochondrial fusion, do not survive beyond
midgestation [40–42]. OPA1 mutations in humans cause
autosomal dominant optic atrophy (ADOA) characterised by
the degeneration of retinal ganglion cells and the optic nerve
axons [43].
It was long assumed that axons lack the protein synthesis
machinery required for organelle and protein biogenesis
and thus the neuronal cell body would operate as this site,
probably close to the nucleus, followed by distribution of
the organelle to the axons [44]. However, recent evidence
suggests that local protein synthesis can occur in axons
[45]. Newly synthesised mtDNA has been shown to be
present not only in the cell body but throughout axons.
The authors also show that Drp1, an essential mitochondrial
fission protein, is present in axonal mitochondria. It is
probable that newly synthesised mitochondria, supported
by an increase in anterograde transport, fuse with already
immobile mitochondria at specific energy-demanding sites.
How important each of the above processes are for the
mitochondrial changes following demyelination needs to be
further investigated.
6. Mitochondrial Changes in Multiple Sclerosis
MS is the most common demyelinating disease of the central
nervous system and, as such, much can be learnt from
studies of the demyelinated axons [46]. Demyelination inMS
classically occurs with inflammation and is associated with
axonal loss which underlies neurological impairment in MS
[47]. Demyelinated lesions associated with various degrees
of inflammation, represent the pathological hallmarks of
the disease which have been studied since the 19th century.
Axonal degeneration is most prevalent in active lesions
where inflammation is greatest. In chronic lesions, many
surviving axons remain chronically demyelinating with only
a few undergoing degeneration at any given time point.
Axonal injury is highlighted by dephosphorylation of neu-
rofilament side arms and has been observed in models of
de/dysmyelination [48] and in acute and chronic MS lesions
[49]. In addition, accumulation of beta-amyloid precursor
protein (β-APP) has been shown to be a marker for axonal
damage in cases of diﬀuse axonal injury [50]. The protein
is known to be transported by fast axonal transport which
is disrupted in axonal injury leading to accumulation of
organelles and intra-axonal proteins around the site of injury
[51]. It is only recently that mitochondrial changes have been
studied in these axons.
Mitochondrial activity in the form of complex IV has
been shown to be increased in inactive areas of chronic
lesions associated with an increase of mitochondrial mass
(Figure 1) [52, 53]. The increase in complex IV has been
noted using several biochemical techniques [54]. Besides the
activity and density, the mobility of mitochondria within
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Figure 2: Mitochondrial dysfunction in MS and its models. Inflammation and the resulting toxic environment can have multiple eﬀects on
mitochondria includingmtDNA damage (left arrow) and respiratory chainmodifications (right arrow). Increased mtDNA copy number and
mtDNA deletions have been observed in MS, which may be a related phenomenon. Actual respiratory chain defects are observed where all
but complex II (blue) have both nuclear and mitochondrial DNA-encoded subunits. Defects include protein nitration aﬀecting complexes
I and IV observed in EAE, reduction in complex I activity in chronic lesions with reductions in complex I and III in nonlesional motor
cortex. Complex IV activity is increased, along with mitochondrial mass, in chronic axons within nonpathological axons whilst a reduction
is observed in pathological axons. The recognised production of reactive oxygen species particularly stemming from complex I and III, along
with complex inhibition by nitric oxide and peroxynitrite, a result of chronic inflammation, points to the high vulnerability of mitochondria
in MS.
axons may also be influenced by demyelination. The expres-
sion of axon-specific mitochondrial docking protein, syn-
taphilin, in chronic lesions indicates a potentially immobile
reservoir that supplies the necessary energy in demyelinated
axons [52]. These axons were morphologically intact, except
for demyelination, and did not show an accumulation of β-
APP. The fact that the above mitochondrial changes were
observed in approximately 50% of morphologically intact
axons that were phosphorylated provides support for the
adaptive or compensatory theory.
Complex IV defects have been noted in both nonphos-
phorylated and APP-positive chronically demyelinated axons
with an associated decrease of mitochondrial mass in the
former but not latter case, suggesting diﬀering mechanisms
(Figure 2) [52]. Another study finds agreement with the
reduction in ATP synthase expression in MS lesions [55].
Enhanced immunoreactivity of themitochondrial heat shock
protein (mtHSP70) in chronic lesions has been noted
indicating an environment of oxidative stress [53, 56].
Although not directly located to axons, other mito-
chondrial defects have been shown in MS tissue including
complex I dysfunction in white matter lesions [54] as
well as reduced complex I and complex III dysfunction
in nonlesional motor cortex [57]. This study based on
gene expression profiles, revealed a decrease in nuclear
encoded subunits of complex I, complex III, complex IV,
and ATP synthase (Figure 2). Whilst this was reflected
in the reduced activities of complex I and complex III
whilst complex IV activity remained the same suggesting a
compensatory mechanism. Furthermore, in white matterMS
lesions, oxidative damage to mtDNA has been reported [54].
The compensatory mitochondrial changes in chronic lesions
appear to be an adaptive process to the demyelination-
induced energy changes that we have discussed previously.
The increase in complex IV, which has been shown in a
number of studies, may also result from a reduction in other
complex activities, though whether this is enough to sustain
ATP production over a period of time is unknown. The
adaptive changes of mitochondria in demyelinated axons,
however, will increase the vulnerability of these axons to
further energy defects. The mitochondrial defects are likely
to compromise the function and structure of the surviving
demyelinated axons in MS, contributing to the neurological
disability and its progression.
7. Mechanisms of Axonal Degeneration
Resulting from Demyelination
MS is viewed as a disease of two stages with vast axonal
loss in the acute stage, associated with inflammation [30,
49]. Direct T-cell cytotoxicity, matrix metalloproteins, and
cytokines have all been implicated in axonal transaction
[58–60]. Incomplete and failure of remyelination results
in gradual slow-burning loss of chronically demyelinated
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axons which significantly contributes to global axonal loss
[61], a mechanism that has also been observed in the
normal-appearing white matter [62]. In the chronic stage
of disease, a cumulative loss of axons over many years
is observed despite a decrease in inflammatory activity.
Thus, it is understood that this represents a slow-burning
axonal disruption phenomenon to the point where the CNS
cannot compensate. The exact mechanism through which
chronically demyelinated axons degenerate is not known.
There is no doubt that sodium channels have an
important role to play, both in restoring conduction in
demyelinated axons and in their degeneration (Figure 2).
It is hypothesised that the accumulation of sodium in the
axon can lead to reversal of the sodium-calcium exchanger
resulting in potentially lethal calcium levels [63]. Evidence
for this initial mechanism is observed in postmortem tissue
of acute MS lesions where APP positive axons are associated
with co-localisation of Nav1.6 channels and the Na+/Ca2+
exchanger [64]. Elevated calcium levels are further exacer-
bated by an increase in expression of N-type voltage-gated
calcium channels in MS [65]. Calcium can activate multiple
pathways including those of calpains of which high levels
are recognised to be a final common pathway to cell death
[13, 66]. Calpain inhibitors, preventing axonal loss, identify
the calcium-mediated pathway as the final step toward axonal
degradation [67]. Evidence for the importance of sodium
channels in axonal degeneration stems from a number of
in vivo studies which show axonal protection as a result of
the use of sodium channel blockers [68–71]. Loss of axons
was ameliorated in the corticospinal tract of EAE animals
when phenytoin treatment was given [70] which coincided
with improving clinical outcomes. A protection against
reduced conduction velocity was also observed. Flecainide
and lamotrigine have also shown this eﬀect in the same
model with an improved functional outcome and reduction
in neurological deficit, respectively, [68, 69]. It has been
noted that exacerbation of EAE followed the withdrawal of
two sodium channel blockers, phenytoin and carbamazepine
[72] which was probably due to the associated marked
increase in inflammatory cells.
A recent clinical trial of lamotrigine in secondary
progressive MS patients produced intriguing results [73].
The primary outcome measure, white matter volume, and
whole brain volume, showed an unexpected loss of partial
cerebral volume in the treatment group. This diﬀerence
between treated group and controls was no longer apparent
once lamotrigine was discontinued, the whole brain volume
increased in the treated group. As sodium channels are
expressed in other cell types including immune cells, the
outcome measurement of brain volume may be eﬀected by
oedema and loss of inflammatory cells as well as direct eﬀects
on neurodegeneration. For instance, the administration of
phenytoin decreases the number of inflammatory cells by
75% [74], which may explain brain volume decreases in the
treatment group.
Complementary to the hypothesis of increased axonal
sodium via persistent sodium entry through Nav1.6, is that
of the lack of the sodium-potassium ATPase on some chron-
ically demyelinated axons. This is not a rare phenomenon
with more than half of chronic lesions containing axons in
which only 50% express the Na+/K+ ATPase [5]. In these
axons, already high sodium axonal levels are exacerbated by
the failure to extrude sodium via the Na+/K+ ATPase [75].
The fact that these axons exist at all in chronic lesions is
interesting. One of the reasons may be the lack of Nav1.6
channels along the axolemma, as only a third of axons in
chronic lesions express Nav1.6 and do so only in a patchy
rather than continuous pattern. These axons do not appear
to be degenerating, highlighted by the lack of positive APP
staining. Further evidence comes from the lack of association
with the sodium-calcium exchanger with these axons[76]. It
is probable that rather than suﬀering from degeneration, they
lack the capacity to electrically conduct as the Na+/K+ ATPase
is responsible for returning the axonal membrane potential
to normal following an action potential.
Mitochondrial adaptations in demyelinated axons appear
crucial to maintaining the axonal integrity and to preventing
oxidative damage [52]. This is a point often missed but
may turn out to be just as important as an increase in
energy demand. In those axons with cytoskeletal changes
induced by demyelination mitochondrial function is of high
importance in order to facilitate the operation of the sodium-
potassium ATPase. An energy-deficient state mediated by
any mode of mitochondria dysfunction will render the axon
nonconductive. Indeed nitric oxide, an inhibitor of complex
IV, has been shown to contribute to axonal dysfunction and
degeneration [55, 77].
Mitochondrial changes may have an underlying yet
under appreciated role in MS and may explain the lack of
consistent relationship between inflammation, demyelina-
tion, and axonal loss. Indeed, conduction block rather than
axonal loss has been shown to occur following demyelination
[78]. Energy deficiency or mitochondrial defects may cause
conduction block particularly in demyelinated axons [79].
The preferential loss of small-diameter axons in MS with
relative preservation of large axons may also be explained
by these mitochondrial changes. The relatively reduced
volume-to-surface-area ratio in small axons may indicate
that small-diameter axons do not have the same capacity for
mitochondrial changes as their large axon counterparts.
8. Conclusions
Mitochondria’s multiple functions implicate them as crucial
players in a healthy central nervous system, and their func-
tional failure, therefore, can result in catastrophic events, as
evident in primary mitochondrial disorders. Energy changes
associated with demyelination and dysmyelination including
the redistribution of ion channels and pumps requires
an associated increase in mitochondria. Neuropathological
studies and evidence from animal models suggest that
demyelinated axons are heavily reliant on mitochondria to
fulfil both energy demands and oxidative stress protection.
Indirect observations point to the fact that this is an essential
requirement of the axon rather than a pathogenic event.
An energy deficit is likely to lead to an accumulation of
sodium in axoplasm, reversal of sodium/calcium exchange,
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and axonal degeneration. An energy deficit may be the result
of not just oxidative phosphorylation defects but also altered
mitochondrial transport, fission, fusion, and biogenesis.
Given the limitations of sodium channel blockade and the
important role of mitochondria in CNS disorders with
demyelination, protection of axonal mitochondria seems a
priority to preserve demyelinated axons, and developing
treatments warrants further investigation.
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